(Q38537853)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

0 references

1 reference

title

Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Laura J Carbone

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Peter W Angus

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

1 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology and Hepatology

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

23-31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic fatty liver disease

18 February 2020

cites work

1 reference

Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae

21 January 2018

1 reference

Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

21 January 2018

1 reference

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

Potential of incretin-based therapies for non-alcoholic fatty liver disease

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

The biology of incretin hormones

21 January 2018

1 reference

Exenatide exerts a potent antiinflammatory effect

21 January 2018

1 reference

Sitagliptin exerts an antinflammatory action

21 January 2018

1 reference

A fresh look at NASH pathogenesis. Part 1: the metabolic movers.

21 January 2018

1 reference

Review: The role of insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease

21 January 2018

1 reference

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

21 January 2018

1 reference

Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

21 January 2018

1 reference

Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.

21 January 2018

1 reference

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

21 January 2018

1 reference

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

21 January 2018

1 reference

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

21 January 2018

1 reference

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

21 January 2018

1 reference

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus

21 January 2018

1 reference

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

21 January 2018

1 reference

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

21 January 2018

1 reference

Publication bias in clinical trials due to statistical significance or direction of trial results

21 January 2018

1 reference

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGH.13026

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26111358%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference